-
Something wrong with this record ?
9-Norbornyl-6-chloropurine is a novel antileukemic compound interacting with cellular GSH
P. Placková, N. Rozumová, H. Hrebabecky, M. Sála, R. Nencka, T. Elbert, A. Dvoráková, I. Votruba, H. Mertlíková-Kaiserová,
Language English Country Greece
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
PubMed
23898074
Knihovny.cz E-resources
- MeSH
- Biological Transport drug effects MeSH
- Caco-2 Cells MeSH
- Epithelial Cells drug effects metabolism MeSH
- Glutathione metabolism MeSH
- Glutathione Transferase antagonists & inhibitors metabolism MeSH
- Cytochrome P-450 Enzyme Inhibitors MeSH
- Leukemia drug therapy pathology MeSH
- Humans MeSH
- Antineoplastic Agents chemistry pharmacology therapeutic use MeSH
- Purines chemistry pharmacology therapeutic use MeSH
- Drug Screening Assays, Antitumor MeSH
- Cytochrome P-450 Enzyme System metabolism MeSH
- Chromatography, High Pressure Liquid MeSH
- Xanthine Oxidase antagonists & inhibitors metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
AIM: 6-Chloropurines substituted at position 9 with bicyclic skeletons represent promising chemotherapeutic agents. We explored the metabolism and membrane transport of 9-norbornyl-6-chloropurine (NCP) aiming to understand its mechanism of action. MATERIALS AND METHODS: The metabolism of NCP was studied in vitro in whole cells (CCRF-CEM), cellular extracts, subcellular fractions and purified enzymes. Transport experiments were conducted in Caco-2 cell monolayers. RESULTS: Three metabolites were identified, a glutathione conjugate (NCP-GS), NCP-cysteinylglycine and NCP-cysteine. Both glutathione-S-transferase inhibition and glutathione (GSH) depletion prevented metabolite formation and increased the cytotoxicity of NCP. Transepithelial transport (Caco-2) indicated good permeability, with Papp (12.6±0.3) ×10(-5) cm/s. Importantly, the drug induced glutathione depletion in treated cells and affected the activity of several GSH-dependent enzymes. CONCLUSION: The novel nucleoside analog NCP represents a promising orally available antileukemic agent, acting through lowering of GSH levels in tumor cells.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040650
- 003
- CZ-PrNML
- 005
- 20140108102432.0
- 007
- ta
- 008
- 140107s2013 gr f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)23898074
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Placková, Pavla
- 245 10
- $a 9-Norbornyl-6-chloropurine is a novel antileukemic compound interacting with cellular GSH / $c P. Placková, N. Rozumová, H. Hrebabecky, M. Sála, R. Nencka, T. Elbert, A. Dvoráková, I. Votruba, H. Mertlíková-Kaiserová,
- 520 9_
- $a AIM: 6-Chloropurines substituted at position 9 with bicyclic skeletons represent promising chemotherapeutic agents. We explored the metabolism and membrane transport of 9-norbornyl-6-chloropurine (NCP) aiming to understand its mechanism of action. MATERIALS AND METHODS: The metabolism of NCP was studied in vitro in whole cells (CCRF-CEM), cellular extracts, subcellular fractions and purified enzymes. Transport experiments were conducted in Caco-2 cell monolayers. RESULTS: Three metabolites were identified, a glutathione conjugate (NCP-GS), NCP-cysteinylglycine and NCP-cysteine. Both glutathione-S-transferase inhibition and glutathione (GSH) depletion prevented metabolite formation and increased the cytotoxicity of NCP. Transepithelial transport (Caco-2) indicated good permeability, with Papp (12.6±0.3) ×10(-5) cm/s. Importantly, the drug induced glutathione depletion in treated cells and affected the activity of several GSH-dependent enzymes. CONCLUSION: The novel nucleoside analog NCP represents a promising orally available antileukemic agent, acting through lowering of GSH levels in tumor cells.
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a biologický transport $x účinky léků $7 D001692
- 650 _2
- $a Caco-2 buňky $7 D018938
- 650 _2
- $a vysokoúčinná kapalinová chromatografie $7 D002851
- 650 _2
- $a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a epitelové buňky $x účinky léků $x metabolismus $7 D004847
- 650 _2
- $a glutathion $x metabolismus $7 D005978
- 650 _2
- $a glutathiontransferasa $x antagonisté a inhibitory $x metabolismus $7 D005982
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a leukemie $x farmakoterapie $x patologie $7 D007938
- 650 _2
- $a puriny $x chemie $x farmakologie $x terapeutické užití $7 D011687
- 650 _2
- $a xanthinoxidasa $x antagonisté a inhibitory $x metabolismus $7 D014969
- 650 _2
- $a inhibitory cytochromu P450 $7 D065607
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rozumová, Nela $u -
- 700 1_
- $a Hrebabecky, Hubert $u -
- 700 1_
- $a Sála, Michal $u -
- 700 1_
- $a Nencka, Radim $u -
- 700 1_
- $a Elbert, Tomás $u -
- 700 1_
- $a Dvoráková, Alexandra $u -
- 700 1_
- $a Votruba, Ivan $u -
- 700 1_
- $a Mertlíková-Kaiserová, Helena $u -
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 33, č. 8 (2013), s. 3163-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23898074 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20140108103132 $b ABA008
- 999 __
- $a ok $b bmc $g 1005046 $s 839162
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 33 $c 8 $d 3163-8 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- LZP __
- $a Pubmed-20140107